5/05/2009
MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Results Showing Burden of RSV Disease Presented at Pediatric Academic Societies’ Annual Meeting
BALTIMORE, May 5 /PRNewswire/ — MedImmune today announced results from a recent study it sponsored, performed by the Kaiser Permanente Division of Research in Oakland, CA, assessing risk factors for respiratory syncytial virus (RSV) infection requiring medical treatment in infants born at 33 weeks gestational age [GA]–>Baltimore, Maryland
